New diabetes clinical trial: A Phase 3 Randomized, Controlled Study of Oral Ladarixin in New-onset Type 1 Diabetes and a Low Residual β-cell Function

Published on: November 13, 2020 at 10:30PM
Condition:   New-onset type1 Diabetes
Interventions:   Drug: Ladarixin;   Drug: Placebo
Sponsor:   Dompé Farmaceutici S.p.A
Not yet recruiting
https://ift.tt/36wU0XJ